Preparat: Eldepryl®, Emsam, EMSAM, Selegilin Mylan
ATC kod: N04BD01
Substanser: selegilin, selegilinhydroklorid
Det saknas publicerade kontrollerade studies om skillnader mellan könen avseende effekt för selegilin. Farmakokinetiskt finns dock ingen påvisad könsskillnad.
The reported incidence and prevalence of Parkinson’s disease (PD) is slightly higher in men than in women. It seems that men develop PD earlier in life compared to women. Several possible explanations behind these sex differences have been suggested; the protective role of estrogens in premenopausal women, and different profiles of risk factors (environmental and/or genetic). Sex differences in clinical presentations of PD have also been reported. Since the activities of daily living might differ between men and women with PD, different treatment strategies can be recommended to men and women with PD .
One review found no sex-related difference in the pharmacokinetics of selegiline following a single oral dose of selegiline 10 mg to six elderly men and six elderly women (age 60-85 years) . No studies with a clinically relevant sex analysis regarding the dosing of selegiline have been found.
No studies with a clinically relevant sex analysis regarding the effects of selegiline have been found.
The increased risk of impulse control disorder with use of dopamine agonists is well known [2-6]. One observational study on dopamine agonists (n=642, approx. 2/3 men) reports a higher frequency of impulse control disorder in men compared to women in patients using dopamine agonists .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Fler män än kvinnor hämtade ut tabletter innehållande selegilin (ATC-kod N04BD01) på recept i Sverige år 2019, totalt 278 män och 163 kvinnor .
Faktagranskat av: Diana Rydberg, Carl-Olav Stiller
Godkänt av: Karin Schenck-Gustafsson